Understanding Cystinosis, Clinical Characteristics and Hypothyroidism Prevalence in Iraqi Pediatric Patients
Khamees M. Al-Dulaimy 1, Zaynab Hameed Ibrahim 1, Bassim Mohammed Salman 1*
Journal of Angiotherapy 8(3) 1-9 https://doi.org/10.25163/angiotherapy.839518
Submitted: 13 February 2024 Revised: 27 March 2024 Published: 30 March 2024
Abstract
Background: Cystinosis, an autosomal recessive lysosomal storage disease, leads to the abnormal accumulation of cystine, primarily affecting the kidneys. Despite various treatments, including cysteamine therapy, renal replacement, and hormonal interventions, no curative treatment exists. Hypothyroidism is a common complication in cystinosis patients, but its prevalence and associations require further investigation. This study aimed to assess the prevalence of hypothyroidism in cystinosis patients and identify associated risk factors. Methods: A six-month cross-sectional study was conducted at Al-Ramadi Teaching Hospital, Iraq, involving 92 cystinosis patients. Data were collected from patient records, and thyroid dysfunction was defined by abnormal thyroid hormone levels. Results: Hypothyroidism prevalence among cystinosis patients was 40.2%. It significantly increased with patient age and age at cystinosis diagnosis, reaching 85.7% and 87.5% in patients over 10 years and diagnosed after 2 years of age, respectively. A positive family history of cystinosis correlated with higher hypothyroidism prevalence. Conclusion: Hypothyroidism is prevalent (40.2%) in cystinosis patients, particularly in older individuals with delayed diagnosis or cysteamine initiation, and those with a family history of the disease. Timely diagnosis, early cysteamine therapy initiation, and regular monitoring for hypothyroidism are essential for managing cystinosis-associated endocrine complications. Further research should explore additional factors influencing hypothyroidism in cystinosis patients to optimize treatment and outcomes.
Keywords: Cystinosis, Hypothyroidism, Cysteamine, Renal Dysfunction, Genetic Mutation (CTNS gene)
References
Ariceta G, Giordano V, Santos F. Effects of long-term cysteamine treatment in patients with cystinosis. Pediatric Nephrology. 2019;34(4):571-8.
Ariceta G, Giordano V, Santos FJPN. Effects of long-term cysteamine treatment in patients with cystinosis. 2019;34(4):571-8.
Azat NFAJTIPMJ. Natural History of Symptomatically Treated Children with Cystinosis. 2012;11:253-7.
Bäumner S, Weber LTJFip. Natinal Library of medicine.gov. Nephropathic Cystinosis: symptoms, treatment, and perspectives of a systemic disease. 2018;6:58. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861330/.
Bengali M, Goodman S, Sun X, Dohil MA, Dohil R, Newbury R, et al. Non-invasive intradermal imaging of cystine crystals in cystinosis. 2021;16(3):e0247846.
Besouw M, Levtchenko EJMP. Growth retardation in children with cystinosis. 2010;62(3):307-13.
Besouw MT, Kremer JA, Janssen MC, Levtchenko ENJF, sterility. Fertility status in male cystinosis patients treated with cysteamine. 2010;93(6):1880-3.
Besouw MT, Van Dyck M, Cassiman D, Claes KJ, Levtchenko ENJPn. Management dilemmas in pediatric nephrology: Cystinosis. 2015;30(8):1349-60.
Brodin-Sartorius A, Tête M-J, Niaudet P, Antignac C, Guest G, Ottolenghi C, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney International. 2012;81(2):179-89.
Cherqui S. Cysteamine therapy: a treatment for cystinosis, not a cure. Kidney international. 2012;81(2):127-9.
Cochat P, Pichault V, Bacchetta J, Dubourg L, Sabot J-F, Saban C, et al. Nephrolithiasis related to inborn metabolic diseases. 2010;25(3):415-24.
Cystinosis: Practice Essentials B, Pathophysiology. Emedicine.medscape.com. . Cystinosis 2020. Available from: https://emedicine.medscape.com/article/981650-overview.
Di Cosmo C, Liao X-H, Dumitrescu AM, Philp NJ, Weiss RE, Refetoff SJTJoci. Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion. 2010;120(9):3377-88.
Elmonem MA, Mahmoud IG, Mehaney DA, Sharaf SA, Hassan SA, Orabi A, et al. link.springer.com.Lysosomal storage disorders in Egyptian children. 2016;83(8):805-13.Available from :https://link.springer.com/article/10.1007/s12098-015-2014-x
Elmonem MA, Veys KR, Soliman NA, van Dyck M, van den Heuvel LP, Levtchenko. Natinal Library of medicine.gov. Cystinosis: a review. 2016;11(1):1-17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/.
Emma F, Nesterova G, Langman C, Labbé A, Cherqui S, Goodyer P, et al. Nephropathic cystinosis: an international consensus document. 2014;29(suppl_4):iv87-iv94.
Florenzano P, Jimenez M, Ferreira CR, Nesterova G, Roberts MS, Tella SH, et al. Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. Journal of the American Society of Nephrology : JASN. 2020;31(9):2184-92. Gérard A-C, Denef J-F, Colin I, van den Hove M-FJEjoe. Evidence for processing of compact insoluble thyroglobulin globules in relation with follicular cell functional activity in the human and the mouse thyroid. 2004;150(1):73-80.
Gahl WA, Balog JZ, Kleta RJAoim. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. 2007;147(4):242-50.
Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Molecular genetics and metabolism. 2000;71(1-2):100-20.
Gahl WA, Thoene JG, Schneider JAJNEJoM. Cystinosis. 2002;347(2):111-21.
Gaide Chevronnay HP, Janssens V, Van Der Smissen P, Liao X, Abid Y, Nevo N, et al. A mouse model suggests two mechanisms for thyroid alterations in infantile cystinosis: decreased thyroglobulin synthesis due to endoplasmic reticulum stress/unfolded protein response and impaired lysosomal processing. 2015;156(6):2349-64.
Gaide Chevronnay HP, Janssens V, Van Der Smissen P, Liao X, Abid Y, Nevo N, et al. A mouse model suggests two mechanisms for thyroid alterations in infantile cystinosis: decreased thyroglobulin synthesis due to endoplasmic reticulum stress/unfolded protein response and impaired lysosomal processing. Endocrinology. 2015;156(6):2349-64.
Galina Nesterova MaWAG, MD, PhD. Cystinosis 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1400/.
Gérard AC, Denef JF, Colin IM, van den Hove MF. Evidence for processing of compact insoluble thyroglobulin globules in relation with follicular cell functional activity in the human and the mouse thyroid. 2004;150(1):73-80.
Hult M, Darin N, von Döbeln U, Månsson JEJAP. Epidemiology of lysosomal storage diseases in Sweden. 2014;103(12):1258-63.
Hussein HJ, Salih KH, Hasan AM. Infantile Nephropathic Cystinosis in Sulaimani Pediatric Teaching Hospital: A Retrospective Cohort Study. Kurdistan Journal of Applied Research. 2018;3(1):5-8.
Hussein HJ, Salih KH, Hasan AMJKJoAR. Infantile Nephropathic Cystinosis in Sulaimani Pediatric Teaching Hospital: A Retrospective Cohort Study. 2018;3(1):5-8.
Jézégou A, Llinares E, Anne C, Kieffer-Jaquinod S, O’Regan S, Aupetit J, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. 2012;109(50):E3434-E43.
Kalatzis V, Cherqui S, Antignac C, Gasnier BJTEj. Cystinosin, the protein defective in cystinosis, is a H+-driven lysosomal cystine transporter. 2001;20(21):5940-9.
Kapelari K, Kirchlechner C, Högler W, Schweitzer K, Virgolini I, Moncayo R. Pediatric reference intervals for thyroid hormone levels from birth to adulthood: a retrospective study. BMC endocrine disorders. 2008;8(1):1-10.
Keser AG, Topaloglu R, Bilginer Y, Besbas NJMP. Long-term endocrinologic complications of cystinosis. 2014;66:123-30.
Langman CB, Greenbaum LA, Sarwal M, Grimm P, Niaudet P, Descheˆnes G, et al. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. 2012;7(7):1112-20.
Levtchenko E, Servais A, Hulton SA, Ariceta G, Emma F, Game DS, et al. Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients. Clinical kidney journal. 2022;15(9):1675-84.
Levtchenko E, Van Den Heuvel L, Emma F, Antignac CJEJoHG. Clinical utility gene card for: cystinosis. 2014;22(5):713-.
Levtchenko EJTJoP. Endocrine complications of cystinosis. 2017;183:S5-S8.
Liang H, Baudouin C, Hassani RTJ, Brignole-Baudouin F, Labbe AJIo, science v. Photophobia and corneal crystal density in nephropathic cystinosis: an in vivo confocal microscopy and anterior-segment optical coherence tomography study. 2015;56(5):3218-25.
Nesterova G, Gahl WA. Cystinosis: the evolution of a treatable disease. Pediatr Nephrol. 2013;28(1):51-9. Cystinosis: Practice Essentials B, Pathophysiology. Emedicine.medscape.com. Available from: https://emedicine.medscape.com/article/981650-overview.
Nesterova G, Gahl WA. Natinal Library of medicine.gov. Cystinosis: the evolution of a treatable disease. Pediatr Nephrol. 2013 Jan;28(1):51-9. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/.
Nesterova G, Gahl WJPn. link.springer.com. Nephropathic cystinosis: late complications of a multisystemic disease. 2008;23(6):863-78.Available from: https://link.springer.com/article/10.1007/s00467-007-0650-8
O'Connell N, Oh J, Arbeiter K, Büscher A, Haffner D, Kaufeld J, et al. Patients With Infantile Nephropathic Cystinosis in Germany and Austria: A Retrospective Cohort Study. Frontiers in medicine. 2022;9:86.
Özkan B, Çayir A, Kosan C, Alp HJJocripe. Cystinosis presenting with findings of Bartter syndrome. 2011;3(2):101.
Pape L, Pape A, Weber L, Arbeiter K, Haffner D, Tönshoff B, et al. Cystinose. 2017;12(3):223-9.
Segni MJE. Disorders of the thyroid gland in infancy, childhood and adolescence. 2017.
Servais A, Moriniere V, Grünfeld J-P, Noël L-H, Goujon J-M, Chadefaux-Vekemans B, et al. Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping. 2008;3(1):27-35.
Soliman NA, Elmonem MA, Heuvel Lvd, Abdel Hamid RH, Gamal M, Bongaers I, et al. Mutational spectrum of the CTNS gene in Egyptian patients with nephropathic cystinosis. JIMD Reports, ; 2014,Volume 14: Springer. p. 87-97.
Tsilou ET, Rubin BI, Reed G, Caruso RC, Iwata F, Balog J, et al. Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy. 2006;113(6):1002-9.
Tsilou ET, Rubin BI, Reed GF, Iwata F, Gahl W, Kaiser-Kupfer MIJC. Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis. 2002;21(2):173-6.
Vaisbich MH, Koch VH. Report of a Brazilian multicenter study on nephropathic cystinosis. Nephron Clinical Practice. 2010;114(1):c12-c8.
Van den Hove M-F, Croizet-Berger K, Tyteca D, Selvais C, de Diesbach P, Courtoy PJJTJoCE, et al. Thyrotropin activates guanosine 5′-diphosphate/guanosine 5′-triphosphate exchange on the rate-limiting endocytic catalyst, Rab5a, in human thyrocytes in vivo and in vitro. 2007;92(7):2803-10.
Veys KR, D’Hauwers KW, van Dongen AJ, Janssen MC, Besouw MT, Goossens E, et al. First successful conception induced by a male cystinosis patient. JIMD Reports, Volume 38: Springer; 2017. p. 1-6.
Veys KR, Elmonem MA, Arcolino FO, van den Heuvel L, Levtchenko EJCoip. Nephropathic cystinosis: an update. 2017;29(2):168-78.
Viltz L, Trauner DAJTJop. Effect of age at treatment on cognitive performance in patients with cystinosis. 2013;163(2):489-92.
Wilmer MJ, Schoeber JP, van den Heuvel LP, Levtchenko ENJPn. Cystinosis: practical tools for diagnosis and treatment. 2011;26(2):205-15.
View Dimensions
View Altmetric
Save
Citation
View
Share